3-Aminopyridines

Delavirdine (DLV) (brand name Rescriptor) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that was marketed by ViiV Healthcare. It was used as part of highly active antiretroviral therapy (HAART) for the treatment of HIV-1 in the late 1990s and early 2000s. It is presented as the mesylate. The recommended dosage is 400 mg (as four 100-mg tablets or two 200-mg tablets) three times a day.

Amifampridine phosphate is used as a drug, predominantly in the treatment of a number of rare muscle diseases. The free base form of the drug has been used to treat congenital myasthenic syndromes and approved by the FDA for Lambert–Eaton myasthenic syndrome (LEMS) through compassionate use programs since the 1990s and was recommended as a first line treatment for LEMS in 2006, using ad hoc forms of the drug, since there was no marketed form.

3-Aminopyridine is an aminopyridine. It is a colorless solid.

Flupirtine is an aminopyridine that functions as a centrally acting non-opioid analgesic that was originally used as an analgesic for acute and chronic pain but in 2013 due to issues with liver toxicity, the European Medicines Agency restricted its use to acute pain, for no more than two weeks, and only for people who cannot use other painkillers. In March 2018, marketing authorisations for flupirtine were withdrawn following a European Medicines Agency recommendation based on the finding that the restrictions introduced in 2013 had not been sufficiently followed in clinical practice, and case

Atevirdine is a non-nucleoside reverse transcriptase inhibitor that has been studied for the treatment of HIV.

Triapine (also known as 3-aminopyridine-2-carboxaldehyde thiosemicarbazone or 3-AP) is an investigational drug that is being evaluated for the treatment of cancer. It is a thiosemicarbazone derivative of 3-aminopyridine-2-carboxaldehyde. It presents an N-N-S array of donor sites that strongly bind iron, robbing iron-containing enzymes of their prosthetic group.

Netupitant is an antiemetic medication. In the United States, the combinations of netupitant/palonosetron and the prodrug fosnetupitant/palonosetron (both brand name Akynzeo) are approved by the Food and Drug Administration for the prevention of acute and delayed chemotherapy-induced nausea and vomiting, including highly emetogenic chemotherapy such as with cisplatin. In the European Union, the combinations are approved by the European Medicines Agency (EMA) for the same indication.